The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials

Figures & data

Table 1 Characteristics of included studies

Study, published year	Study design	Study site	Study period	Study population	No of patients		Dose regimen
					Nemonoxacin	Comparator	Nemonoxacin	Comparator
van Rensburg et al, 2010^Citation17	Multicenter, randomized, double- blind, non-inferiority trial	South Africa, Taiwan	2006– 2007	Mild to moderate CAP	89 (500 mg) 86 (750 mg)	90	Nemonoxacin 750 mg or 500 mg/day for 7 days	Levofloxacin 500 mg/day for 7 days
Liu et al, 2017^Citation16	Multicenter, randomized, double- blind, non-inferiority trial	China	2009– 2010	Chinese patients with mild to moderate CAP	65 (500 mg) 65 (750 mg)	62	Nemonoxacin 750 or 500 mg/ day for 7–10 days	Levofloxacin 500 mg/day for 7–10 days
Yuan et al, 2017^Citation18	Multicenter, randomized, double-blind,, non- inferiority trial	China, Taiwan	2011– 2012	Chinese patients with CAP	357 (500 mg)	175	Nemonoxacin 500 mg/day for 7–10 days	Levofloxacin 500 mg/day for 7–10 days

Abbreviation: CAP, community-acquired pneumonia

Figure 1 Flow diagram of the study selection process.

Figure 2 Summary of risk of bias.

Figure 3 Risk of bias per study and domain.

Figure 4 The overall clinical cure rates of nemonoxacin and levofloxacin in the treatment of community-acquired pneumonia.

Figure 5 The overall microbiologic response rates of nemonoxacin and levofloxacin in the treatment of community-acquired pneumonia.

Figure 6 The overall risks of treatment-emergent adverse events for nemonoxacin and levofloxacin in the treatment of community-acquired pneumonia.

van RensburgDJPerngRPMithaIHEfficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumoniaAntimicrob Agents Chemother201054104098410620660689

 PubMed Web of Science ®Google Scholar

LiuYZhangYWuJA randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumoniaJ Microbiol Immunol Infect201750681182026748734

 PubMedGoogle Scholar

YuanJMoBMaZSafety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: a Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trialJ Microbiol Immunol Infect2017 piiS1684–1182173015130152

 Google Scholar